Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases
Gespeichert in:
| Veröffentlicht in: | Inflammatory bowel diseases 2021-10, Vol.27 (10), p.1698-1702 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1702 |
|---|---|
| container_issue | 10 |
| container_start_page | 1698 |
| container_title | Inflammatory bowel diseases |
| container_volume | 27 |
| creator | Alayo, Quazim A Khatiwada, Aava Patel, Anish Zulfiqar, Maria Gremida, Anas Gutierrez, Alexandra Rood, Richard P Ciorba, Matthew A Christophi, George Deepak, Parakkal |
| description | |
| doi_str_mv | 10.1093/ibd/izab112 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8682277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ibd/izab112</oup_id><sourcerecordid>2532240725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-c7be5376f66699efb21f8e62ef9278f2f257265e20c1250edee80a41cda2edd13</originalsourceid><addsrcrecordid>eNp9kd9rFDEQx4Motp4--S55koKsTWZ_ZPdFsNeqhYKiFR_DbHZyjewm5yZXuf71jd611BeZh5kv8-E7A1_GXkrxVoquPHb9cOxusJcSHrFDWZdNUbVV9TjPQrWF6Lr2gD2L8acQkKt7yg7KSpQKoD5k2zNrySR3TZ5i5OgH_g0tpS0Pli_D1Dvv_IpfBovGpSx6_sOlK478xIUxrJzhzvMvmBz5FHe7r2RnNCnMW37u7YjThH_FSfhNIz91kTBSfM6eWBwjvdj3Bfv-4exy-am4-PzxfPn-ojCVhFQY1VNdqsY2TdN1ZHuQtqUGyHagWgsWagVNTSCMhFrQQNQKrKQZEGgYZLlg73a-600_0WDynzOOej27CeetDuj0vxvvrvQqXOu2aQGUygZHe4M5_NpQTHpy0dA4oqewiRrqEqASKvcFe7NDzRxinMnen5FC_wlL57D0PqxMv3r42T17l04GXu-AsFn_1-kWOTehMQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532240725</pqid></control><display><type>article</type><title>Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Alayo, Quazim A ; Khatiwada, Aava ; Patel, Anish ; Zulfiqar, Maria ; Gremida, Anas ; Gutierrez, Alexandra ; Rood, Richard P ; Ciorba, Matthew A ; Christophi, George ; Deepak, Parakkal</creator><creatorcontrib>Alayo, Quazim A ; Khatiwada, Aava ; Patel, Anish ; Zulfiqar, Maria ; Gremida, Anas ; Gutierrez, Alexandra ; Rood, Richard P ; Ciorba, Matthew A ; Christophi, George ; Deepak, Parakkal</creatorcontrib><identifier>ISSN: 1078-0998</identifier><identifier>EISSN: 1536-4844</identifier><identifier>DOI: 10.1093/ibd/izab112</identifier><identifier>PMID: 34037225</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Biological Products ; Clinical Brief Reports ; Humans ; Inflammatory Bowel Diseases - drug therapy ; Piperidines - adverse effects ; Piperidines - chemistry ; Piperidines - pharmacology ; Pyrimidines - adverse effects ; Pyrimidines - chemistry ; Pyrimidines - pharmacology</subject><ispartof>Inflammatory bowel diseases, 2021-10, Vol.27 (10), p.1698-1702</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-c7be5376f66699efb21f8e62ef9278f2f257265e20c1250edee80a41cda2edd13</citedby><cites>FETCH-LOGICAL-c412t-c7be5376f66699efb21f8e62ef9278f2f257265e20c1250edee80a41cda2edd13</cites><orcidid>0000-0002-3436-9784 ; 0000-0001-5524-7105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34037225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alayo, Quazim A</creatorcontrib><creatorcontrib>Khatiwada, Aava</creatorcontrib><creatorcontrib>Patel, Anish</creatorcontrib><creatorcontrib>Zulfiqar, Maria</creatorcontrib><creatorcontrib>Gremida, Anas</creatorcontrib><creatorcontrib>Gutierrez, Alexandra</creatorcontrib><creatorcontrib>Rood, Richard P</creatorcontrib><creatorcontrib>Ciorba, Matthew A</creatorcontrib><creatorcontrib>Christophi, George</creatorcontrib><creatorcontrib>Deepak, Parakkal</creatorcontrib><title>Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases</title><title>Inflammatory bowel diseases</title><addtitle>Inflamm Bowel Dis</addtitle><subject>Biological Products</subject><subject>Clinical Brief Reports</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - chemistry</subject><subject>Piperidines - pharmacology</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><issn>1078-0998</issn><issn>1536-4844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd9rFDEQx4Motp4--S55koKsTWZ_ZPdFsNeqhYKiFR_DbHZyjewm5yZXuf71jd611BeZh5kv8-E7A1_GXkrxVoquPHb9cOxusJcSHrFDWZdNUbVV9TjPQrWF6Lr2gD2L8acQkKt7yg7KSpQKoD5k2zNrySR3TZ5i5OgH_g0tpS0Pli_D1Dvv_IpfBovGpSx6_sOlK478xIUxrJzhzvMvmBz5FHe7r2RnNCnMW37u7YjThH_FSfhNIz91kTBSfM6eWBwjvdj3Bfv-4exy-am4-PzxfPn-ojCVhFQY1VNdqsY2TdN1ZHuQtqUGyHagWgsWagVNTSCMhFrQQNQKrKQZEGgYZLlg73a-600_0WDynzOOej27CeetDuj0vxvvrvQqXOu2aQGUygZHe4M5_NpQTHpy0dA4oqewiRrqEqASKvcFe7NDzRxinMnen5FC_wlL57D0PqxMv3r42T17l04GXu-AsFn_1-kWOTehMQ</recordid><startdate>20211018</startdate><enddate>20211018</enddate><creator>Alayo, Quazim A</creator><creator>Khatiwada, Aava</creator><creator>Patel, Anish</creator><creator>Zulfiqar, Maria</creator><creator>Gremida, Anas</creator><creator>Gutierrez, Alexandra</creator><creator>Rood, Richard P</creator><creator>Ciorba, Matthew A</creator><creator>Christophi, George</creator><creator>Deepak, Parakkal</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3436-9784</orcidid><orcidid>https://orcid.org/0000-0001-5524-7105</orcidid></search><sort><creationdate>20211018</creationdate><title>Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases</title><author>Alayo, Quazim A ; Khatiwada, Aava ; Patel, Anish ; Zulfiqar, Maria ; Gremida, Anas ; Gutierrez, Alexandra ; Rood, Richard P ; Ciorba, Matthew A ; Christophi, George ; Deepak, Parakkal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-c7be5376f66699efb21f8e62ef9278f2f257265e20c1250edee80a41cda2edd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biological Products</topic><topic>Clinical Brief Reports</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - chemistry</topic><topic>Piperidines - pharmacology</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alayo, Quazim A</creatorcontrib><creatorcontrib>Khatiwada, Aava</creatorcontrib><creatorcontrib>Patel, Anish</creatorcontrib><creatorcontrib>Zulfiqar, Maria</creatorcontrib><creatorcontrib>Gremida, Anas</creatorcontrib><creatorcontrib>Gutierrez, Alexandra</creatorcontrib><creatorcontrib>Rood, Richard P</creatorcontrib><creatorcontrib>Ciorba, Matthew A</creatorcontrib><creatorcontrib>Christophi, George</creatorcontrib><creatorcontrib>Deepak, Parakkal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Inflammatory bowel diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alayo, Quazim A</au><au>Khatiwada, Aava</au><au>Patel, Anish</au><au>Zulfiqar, Maria</au><au>Gremida, Anas</au><au>Gutierrez, Alexandra</au><au>Rood, Richard P</au><au>Ciorba, Matthew A</au><au>Christophi, George</au><au>Deepak, Parakkal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases</atitle><jtitle>Inflammatory bowel diseases</jtitle><addtitle>Inflamm Bowel Dis</addtitle><date>2021-10-18</date><risdate>2021</risdate><volume>27</volume><issue>10</issue><spage>1698</spage><epage>1702</epage><pages>1698-1702</pages><issn>1078-0998</issn><eissn>1536-4844</eissn><cop>US</cop><pub>Oxford University Press</pub><pmid>34037225</pmid><doi>10.1093/ibd/izab112</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-3436-9784</orcidid><orcidid>https://orcid.org/0000-0001-5524-7105</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0998 |
| ispartof | Inflammatory bowel diseases, 2021-10, Vol.27 (10), p.1698-1702 |
| issn | 1078-0998 1536-4844 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8682277 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Biological Products Clinical Brief Reports Humans Inflammatory Bowel Diseases - drug therapy Piperidines - adverse effects Piperidines - chemistry Piperidines - pharmacology Pyrimidines - adverse effects Pyrimidines - chemistry Pyrimidines - pharmacology |
| title | Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T10%3A28%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20Safety%20of%20Combining%20Tofacitinib%20With%20a%20Biologic%20in%20Patients%20With%20Refractory%20Inflammatory%20Bowel%20Diseases&rft.jtitle=Inflammatory%20bowel%20diseases&rft.au=Alayo,%20Quazim%20A&rft.date=2021-10-18&rft.volume=27&rft.issue=10&rft.spage=1698&rft.epage=1702&rft.pages=1698-1702&rft.issn=1078-0998&rft.eissn=1536-4844&rft_id=info:doi/10.1093/ibd/izab112&rft_dat=%3Cproquest_pubme%3E2532240725%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532240725&rft_id=info:pmid/34037225&rft_oup_id=10.1093/ibd/izab112&rfr_iscdi=true |